Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
2.030
+0.020 (1.00%)
At close: Jan 17, 2025, 4:00 PM
2.050
+0.020 (0.99%)
Pre-market: Jan 21, 2025, 8:57 AM EST
Tharimmune Employees
As of December 31, 2023, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$3,616,932
Market Cap
3.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
THAR News
- 5 weeks ago - Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Accesswire
- 6 weeks ago - Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Accesswire
- 2 months ago - Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Accesswire
- 2 months ago - Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics - Accesswire
- 2 months ago - Tharimmune Announces Upcoming Conference Presentations - Accesswire
- 2 months ago - Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - Accesswire
- 3 months ago - Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Accesswire
- 4 months ago - Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - Accesswire